2024
Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer
Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.Peer-Reviewed Original ResearchVeterans Health AdministrationCharlson Comorbidity IndexNon-prostate cancer mortalityProstate cancer mortalityNonmetastatic prostate cancerComorbidity indexCancer mortalityProvider estimationProstate cancerHealth AdministrationUS Veterans Health AdministrationElectronic health record-based toolsYear of diagnosisRisk of deathObservational cohortMedian ageNonmetastatic cancerPredicting MortalityC-statisticHispanic ethnicityTreatment groupsMortalityCancerNational validationAge
2021
Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States
Holler J, Hakam N, Nabavizadeh B, Sadighian M, Shibley W, Li K, Weiser L, Rios N, Enriquez A, Leapman M, Amend G, Breyer B. Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urology Practice 2021, 9: 56-63. PMID: 37145560, DOI: 10.1097/upj.0000000000000275.Peer-Reviewed Original ResearchUrological cancersActive treatmentCancer campaignsMajor urological cancersPrimary cancer typeCross-sectional studyWilcoxon rank sum testRank sum testRecipient ageMultivariable analysisPatient populationTesticular malignancyMalignancy typeTesticular cancerKidney cancerMedical careCancerCancer typesMedical expensesFinancial burdenOutcomesBladderKruskal-WallisProstateAge